The National Advisory Committee on Immunization is recommending a universal immunization program against respiratory syncytial virus, or RSV, for all infants. This electron microscope image provided by the National Institutes of Health shows human respiratory syncytial virus (RSV) virions, colourized blue, and anti-RSV F protein/gold antibodies, colourized yellow, shedding from the surface of human lung cells. THE CANADIAN PRESS/AP-HO, NIH, National Institute of Allergy and Infectious Diseases, *MANDATORY CREDIT*
The National Advisory Committee on Immunization is recommending a universal immunization program against respiratory syncytial virus, or RSV, for all infants. This electron microscope image provided by the National Institutes of Health shows human respiratory syncytial virus (RSV) virions, colourized blue, and anti-RSV F protein/gold antibodies, colourized yellow, shedding from the surface of human lung cells. THE CANADIAN PRESS/AP-HO, NIH, National Institute of Allergy and Infectious Diseases, *MANDATORY CREDIT*
GACThe National Advisory Committee on Immunization is recommending a universal immunization program against respiratory syncytial virus, or RSV, for all infants.
It says provinces and territories should work toward providing the antibody drug Nirsevimab for all infants before their first RSV season.
But it says they could start by prioritizing the highest-risk infants if cost or access to the antibody is a barrier to implementing a universal program right away.
Babies at highest risk of becoming seriously ill with RSV include those born prematurely, those with certain medical conditions and infants living in crowded conditions or other high-risk settings.
The committee says Nirsevimab should also be prioritized for infants living in remote areas where transportation to get treatment would be difficult if they got severe RSV, including some First Nations, Métis and Inuit communities.
Health Canada authorized Nirsevimab — also known by its brand name Beyfortus — in April 2023.
The national committee also said that pregnant people and their health-care providers could consider a vaccine called RSVpreF, or Abrysvo, which is given during the third trimester to provide protection against RSV for the infant.
This report by °µÍø½ûÇø was first published May 17, 2024.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
°µÍø½ûÇø. All rights reserved.
Get the latest from °µÍø½ûÇø News in your inbox. Select the emails you're interested in below.
A sellout crowd of 15,892 watched the Atlanta Dream on Friday when they faced the …
Health experts, advocates and unions are raising concerns about Alberta’s plan to …
Sorry, an error occurred.
Already Subscribed!
Cancel anytime
Thank you .
Your account has been registered, and you are now logged in.
Check your email for details.
Submitting this form below will send a message to your email with a link to change your password.
An email message containing instructions on how to reset your password has been sent to the email address listed on your account.
No promotional rates found.
Secure & Encrypted
Thank you.
Your gift purchase was successful! Your purchase was successful, and you are now logged in.
| Rate: | |
| Begins: | |
| Transaction ID: |
A receipt was sent to your email.
